Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3032MR)

This product GTTS-WQ3032MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7&ITGAE gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000885.6; NM_000889.3; NM_002208.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695; 3682
UniProt ID P13612; P26010; P38570
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3032MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ457MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ15427MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ2887MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ1263MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ53MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ13153MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ6951MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ13630MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA R4930
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW